BRAIN Biotech AG

XETRA BNN.DE

BRAIN Biotech AG EBIT Margin for the year ending September 30, 2024: -16.57%

BRAIN Biotech AG EBIT Margin is -16.57% for the year ending September 30, 2024, a -38.25% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

BRAIN Biotech AG EBIT Margin for the year ending September 30, 2023 was -11.98%, a -5.27% change year over year.
BRAIN Biotech AG EBIT Margin for the year ending September 30, 2022 was -11.38%, a -118.51% change year over year.
BRAIN Biotech AG EBIT Margin for the year ending September 30, 2021 was -5.21%, a 77.50% change year over year.
BRAIN Biotech AG EBIT Margin for the year ending September 30, 2020 was -23.16%, a -3.39% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

XETRA: BNN.DE

BRAIN Biotech AG

CEO	Mr. Adriaan Moelker
IPO Date	Feb. 9, 2016
Location	Germany
Headquarters	Darmstädter Strasse 34-36
Employees	319
Sector	Healthcare
Industries Biotechnology Biofuel Chemicals & Advanced Materials Dairy & Milk Food & Beverages Non-Alcoholic Beverages Petrochemicals Plastics

Description

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

Key trends

Past 5 years